RxDoctor Payments Data

Olasumbo Oladeru

Psychiatric/Mental Health · Ewing, NJNPI 1083250484

Payments from drug & device makers

$3,886in general payments, 2019–2025

Across 189 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$663
  • Otsuka America Pharmaceutical, Inc.$662
  • AbbVie$653
  • E.r. Squibb & Sons, L.L.C.$364
  • Teva Pharmaceuticals USA, Inc.$334
  • Johnson & Johnson$228
  • plus $982 from 8 others

What the payments were for

  • Food & beverage$3,886100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,886 in reported general payments places this provider in the 90th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$8,350
Medicare patients
17
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$32,939
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$936
Alprazolam54$567
Bupropion XlBupropion Hcl14$562
Olanzapine24$554
Divalproex Sodium14$536
Quetiapine Fumarate23$518
Aripiprazole16$514
Divalproex Sodium ErDivalproex Sodium12$514
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$492
Mirtazapine28$449
Buspirone Hcl22$446
Hydroxyzine Pamoate14$304
Prazosin Hcl14$256
Clonazepam16$255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$228$32,93913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Ewing

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →